New episodes every Tuesday!
GET NEW EPISODES TO YOUR EMAIL
Latest Episode
Living in the Now, with John Doe
Adipiscing elit dapibus, vulpu tate in donec tempor ultricies venenatis erat, aliquam posuere urna habitant rutrum iaculis Euismod maecenas varius. tortor nibh, sit amet tempor nibh finibus et. Aenean eu enim justo. Vestibulum aliquam
Nvidia briefly becomes the first $4 trillion company. How it beat Microsoft and Apple to the crown.
The chip maker’s stock touched an intraday level needed to achieve a $4 trillion market cap, but has since pulled back slightly.
I have $2,000 left at the end of the month. Should I claim Social Security early at 62?
“I’m in relatively good physical shape. I collect 100% VA Disability for mental health at $4,000 per month.”
More older people than children now need caregiving. Governments and employers need to step up.
“Caregiving is no longer a personal issue. It’s a national crisis.”
Microsoft’s stock gets an upgrade. Why these analysts say it’s underappreciated in AI.
The sustaining growth of the company’s AI revenue and cloud platform Azure are not fully priced into the stock, Oppenheimer analysts said.
Stablecoins could hurt bank profits, but not for a while: analyst
The growing use of stablecoins could increase the cost of lending for banks if they have fewer deposits to draw from, Moody’s says.
Home sellers have gotten tired of cutting prices. So they’re yanking their houses off the market.
Home sellers in some of the nation’s worst housing markets are tired of cutting prices. So they’re pulling their listings.
This early-warning indicator is telling the stock market that a recession is more likely
If you’re like many U.S. consumers, you’re more worried now about money.
Goldman identifies three bears that could disrupt the Goldilocks market environment
After a stunning comeback for markets and sentiment, Goldman Sachs places three main risks in the spotlight
Merck dives into COPD treatments with $10 billion purchase of Verona Pharma
Verona Pharma’s stock soars toward a record after $10 billion buyout deal with Merck.
Stay Tuned For Our Latest Episodes
Anean eu enim justo. Vestibulum aliquam hende rit molestie. Mauris malesuada nisi sit amet augue accumsan tincidunt. Maecenas tincidunt aliquam hende rit molestie. Mauris malesuada.
Start Listening Today!
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas varius tortor nibh, sit amet tempor nibh finibus et. Aenean eu enim justo. Vestibulum aliquam hendrerit
